Notice of Results

Abingdon, UNITED KINGDOM


Summit Therapeutics plc 
(‘Summit’ or the ‘Company’)

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019

Oxford, UK, and Cambridge, MA, US, 25 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, will announce its financial results for the fourth quarter and fiscal year ended 31 January 2019 on 27 March 2019.

Summit will host a conference call and webcast the same day to discuss its operational progress at 12:00 noon GMT / 8:00am EDT. Conference call and webcast information will be included in the full year results press release. A replay of the call will also be available through the Company's website, www.summitplc.com, shortly after its conclusion.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson  
   
N+1 Singer (Joint Broker)Tel:+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking
  
   
Bryan Garnier & Co Limited (Joint Broker)Tel:+44 (0)20 7332 2500
Phil Walker / Dominic Wilson

 
  
MSL Group (US)Tel:+1 781 684 6557
Jon Siegal summit@mslgroup.com
   
Consilium Strategic Communications (UK)Tel:+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / summit@consilium-comms.com
Lindsey Neville  

-END-